Module 2: (Q)SAR: Introduction to Methodology and Regulatory Application in Drug Development

Recorded On: 12/23/2025

image
image


(Quantitative) structure-activity relationship [(Q)SAR] modeling has a long history of use in drug development. However, the International Council for Harmonization (ICH) M7 guideline for assessing the mutagenic potential of drug impurities stands as a milestone in the regulatory acceptance of (Q)SAR. The guideline describes how complementary modeling methodologies can be used in combination with expert knowledge to support classifying an impurity as mutagenic or non-mutagenic, which in turn determines acceptable levels of the impurity during synthesis and degradation. The selection of appropriate (Q)SAR models for ICH M7 impurity qualification requires knowledge of how models are constructed and how predictions are generated. Technical considerations such as the molecular descriptors used to interpret chemical structure, the type of algorithm used to extract structure-activity relationships, or the way the model confirms it can make a reliable prediction are critical for the user to understand so that the model output is interpreted correctly. 

Part One of this seminar will provide an introduction to the basic concepts and technical considerations of (Q)SAR modeling. Key concepts, such as reconciling conflicting predictions or applying the OECD Validation Principles to assess model suitability will be covered, as well as the limitations of the methodology. An introduction to expert knowledge and strategies for structural analog searching will be provided along with best practices for the comprehensive reporting of results in regulatory submissions. In addition, this session will provide a pharmaceutical industry perspective on the regulatory use of (Q)SAR, including a general process for evaluating mutagenic potential with an emphasis on impurities, generation of predictions, application of expert knowledge, and final classification. The utility of read-across and case studies will be used to emphasize key concepts and demonstrate best practices. 

Part Two—Supplemental Session will provide an update on the changes to the most recent ICH M7 guidance as well as a review of the main principles of the M7 guidance, including impurity evaluation, hazard assessment and classification, as well as risk characterization and control. During the progression through development, there are occasions where novel impurities may arise due to changed manufacturing processes, or impurities that are discovered after safety studies have been concluded. The EMA has published a reflection paper that covers qualification of non-mutagenic impurities (NMI) using new approach methodologies and methods to set acceptable levels of NMIs. The seminar will also cover a review of the salient points of the EMA paper. 

Lisa D. Beilke, MSPH, PhD, DABT, ATS

Lisa D. Beilke, MSPH, PhD, DABT, ATS

Consultant

Toxicology Solutions, Inc.

Dr. Lisa Beilke has over 25 years of experience working in various fields of toxicology in support of novel therapeutics. She has worked for small contract laboratories, start-up biotechs, as well as large pharma (Pfizer, Gilead). She earned her PhD in Pharmacology & Toxicology from the University of Arizona, as well as her BS and MS (Public Health/Toxicology) degrees from San Diego State University. Dr. Beilke has been an independent consultant with Toxicology Solutions, Inc. for the last 13 years and has focused on providing toxicology services to the pharmaceutical industry, with a specialty in in silico toxicity predictions for potential genotoxic impurities and risk assessment. Dr. Beilke has worked closely with colleagues in the computational toxicology field over the years and has several publications in this field, including collaborations with Leadscope on in silico protocols. As a consultant, Dr. Beilke has worked with clients on various therapeutic areas (dermatology, oncology, metabolic diseases, cardiovascular, etc.) and compound types (e.g., peptides, polymers, antibodies, dye conjugates, etc.).

Dr. Beilke has a long history of involvement with various toxicology organizations. As a diplomat of ABT, she was part of the group that worked on the standardization of the certification examination. She has been a member of the ACT since 1999 and has served on the Education (2009–2011) and Finance Committees (2011–2014), as a Councilor (2016–2018), and was presented with the Young Investigator Award in 2013. She is also on the Editorial Board of the International Journal of Toxicology (2013–present). She is a full member of the SOT, where she is Past President of the Computational Toxicology Specialty Section (CTSS), which she co-developed as a new Specialty Section.

Naomi Kruhlak, PhD

Naomi Kruhlak, PhD

Computational Toxicologist

US FDA

Dr. Naomi Kruhlak has worked for the US FDA’s Center for Drug Evaluation and Research (CDER) as a computational toxicologist for 18 years, developing and applying (quantitative) structure-activity relationship ((Q)SAR) models to support the regulatory review of pharmaceuticals. She is the Scientific Lead for CDER’s Computational Toxicology Consultation Service and is the Principal Investigator on three FDA/CDER Research Collaboration Agreements with commercial (Q)SAR software vendors, as well as an Inter-Agency Agreement with NIH generating in silico-based drug safety predictions. Dr. Kruhlak has published 42 peer-reviewed articles describing data standardization, transformation, and classification for modeling purposes, and the creation and application of (Q)SAR models with chemical interpretability. Dr. Kruhlak holds BSc and PhD degrees in chemistry from the University of Salford, England, and the University of Calgary, Canada, respectively.

Mark Powley, PhD

Mark Powley, PhD

Distinguished Research Scientist

Merck & Co., Inc.

Mark W. Powley received a PhD in toxicology from Purdue University and completed postdoctoral training at the University of North Carolina – Chapel Hill. From 2004 to 2009, he worked in the general toxicology, biochemical toxicology, and genetic toxicology groups at Merck Research Laboratories. In 2009, Mark moved to the US FDA Center for Drug Evaluation and Research (CDER), Office of New Drugs. In addition to reviewing nonclinical data, Mark co-chaired several CDER pharmacology/toxicology subcommittees, including those focused on genetic toxicology and computational toxicology. Mark rejoined Merck Research Laboratories in 2017 and currently works in the genetic toxicology group. His primary role involves supporting both mutagenic and non-mutagenic impurity safety assessment.

Key:

Complete
Failed
Available
Locked
Module 2: (Q)SAR: Introduction to Methodology and Regulatory Application in Drug Development
Module 2: (Q)SAR: Introduction to Methodology and Regulatory Application in Drug Development, Naomi Kruhlak, PhD, and Mark Powley, PhD
Recorded 01/20/2022  |  90 minutes
Recorded 01/20/2022  |  90 minutes As part of your registration, you will have unlimited access to the module recording for 30 days. Your 30-day access period begins when you first access the recording. Once the access period begins, it cannot be reset or restarted. To receive a certificate of completion, you must watch the recording for the minimum required viewing time. Please keep the recording open while viewing, as the system tracks your viewing time during the active session. If you close your browser before meeting the minimum viewing requirement, your viewing progress may not be retained. Once you have met the viewing requirement, the module survey will become available. After completing the survey, you will be able to access and download your certificate of completion. If you have any questions, please contact ACT Headquarters at [email protected].
Module 2: (Q)SAR Review: ICH M7 Updates and EMA Reflection Paper on Qualification of Non-Mutagenic Impurities, Lisa Beilke, MSPH, PhD, DABT, ATS
Recorded 12/23/2025
Recorded 12/23/2025 As part of your registration, you will have unlimited access to the module recording for 30 days. Your 30-day access period begins when you first access the recording. Once the access period begins, it cannot be reset or restarted. To receive a certificate of completion, you must watch the recording for the minimum required viewing time. Please keep the recording open while viewing, as the system tracks your viewing time during the active session. If you close your browser before meeting the minimum viewing requirement, your viewing progress may not be retained. Once you have met the viewing requirement, the module survey will become available. After completing the survey, you will be able to access and download your certificate of completion. If you have any questions, please contact ACT Headquarters at [email protected].
Survey
13 Questions
13 Questions ACT values your feedback. Please help us continue to provide high-quality educational offerings by completing this short survey. The survey will become available after you have met the minimum viewing requirement for the recording. Once you complete the survey, your certificate of completion will become available on your dashboard or for download.
Certificate
No credits available  |  Certificate available
No credits available  |  Certificate available Your certificate of completion will become available after you have met the minimum viewing requirement and completed the module survey.